Protagonist discontinues Phase IIb of PTG-100 for UC

By Jaime De Leon | Mar 30, 2018 | 5:56 PM GMT

Protagonist Therapeutics Inc. (NASDAQ:PTGX) discontinued the Phase IIb PROPEL trial of once-daily PTG-100 to treat moderate to severe ulcerative colitis. Protagonist said it will decide whether to start

Read the full 282 word article

How to gain access

Continue reading with a
two-week free trial.